Related Experiment Video

Updated: Jul 11, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity

Shiwei Deng1, Bettina Kulle, Mehdi Hosseini

  • 1Department of Pharmacology, Johannes Gutenberg University, 55101 Mainz, Germany.

European Journal of Heart Failure
|September 25, 2007
PubMed
Abstract

Insights

Dystrophin deficiency worsens doxorubicin-induced heart damage in mice, highlighting genetic factors in cardiotoxicity. This suggests that cytoskeletal protein variations may influence individual susceptibility to chemotherapy-related heart problems.

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Doxorubicin (DOX) cardiotoxicity limits anthracycline use, potentially linked to genetic factors.
  • Individual susceptibility to DOX-induced cardiomyopathy may be influenced by genetic variations in cardiac proteins.

Purpose of the Study:

  • To investigate the role of dystrophin deficiency in doxorubicin-induced cardiotoxicity.
  • To explore the impact of genetic makeup on susceptibility to chemotherapy-related heart damage.

Main Methods:

  • Chronic doxorubicin treatment in female dystrophin-deficient (MDX) mice and wild-type controls.
  • Assessment of cardiac function (echocardiography) and tissue damage (histopathology).
  • Microarray analysis to investigate gene expression changes.

Main Results:

  • Doxorubicin treatment caused mortality, cardiac insufficiency, and fibrosis, more severely in MDX mice.
  • MDX mice exhibited more pronounced gene expression changes, including those related to cell adhesion, oxidative stress, and immune response.
  • Dystrophin deficiency exacerbated doxorubicin-induced cardiac injury.

Conclusions:

  • Dystrophin deficiency facilitates doxorubicin-induced cardiac injury through mechanisms involving cell adhesion, cytoskeleton, and immune responses.
  • Genetic variants in cytoskeletal proteins may influence human susceptibility to doxorubicin cardiotoxicity.
  • Cardiotoxic drugs might accelerate pre-clinical cardiomyopathies in individuals with cytoskeletal protein deficiencies.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...